Experimental design on product development

Similar documents
Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs

QbD implementation in Generic Industry: Overview and Case-Study

PHARMACEUTICAL MANUFACTURING

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Regulatory Assessment

EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS

Applied Process Understanding in Drug Product Development

Meeting Solid Dose Formulation Challenges

The use of surrogates for dissolution testing for Immediate Release (IR) formulations, when is it feasible?

Design and Dosage Form. Dr. Deny Susanti

Performance Testing of Novel Dosage Forms

At LATITUDE, we only do one thing, and we do it very well.

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany

GDUFA II Pre-ANDA Program Meetings for Complex Products

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

BCS, Biowaivers and Dissolution Test Methodologies

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

Developing new drug products is very expensive, especially

CE 7smart Flow-Through Dissolution System

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

Design of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique

A HYBRID INTELLIGENT SYSTEM FOR FORMULATION OF BCS CLASS II DRUGS IN HARD GELATIN CAPSULES

Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives

Tablet formulation design spaces for direct compression and roller compaction. QbD in Pharmaceutical Development: processes

coating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY

Better wet granulation: development, scale-up and manufacture

Formulation Development & CTM Manufacturing Services

2nd FDA/PQRI Conference on Advancing Product Quality

The Value of High-Functionality Excipients in Continuous Manufacturing Tony Carpanzano, B.S., R. Ph. Director, R&D JRS Pharma, LP, Patterson, NY

Maximizing Roller Compaction Benefits with Proper Excipient Selection

AdaptDose, an innovative platform that reduces product development time and costs by 30% or more

ADVANTAGES OF MULTIPARTICULATES (PELLETS):

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Guidance for Industry

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

Derivation and Justification of Safety Thresholds

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development

Roller Compaction: New trends, challenges and solutions

Providing insight into pharmaceutical formulations

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

CHAPTER 1 PHARMACEUTICAL INDUSTRY

The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.

USP s Perspective on Drug Product Performance Test

FOOD AND DRUGS AUTHORITY

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

Liquisolid Compacts Based Orodispersible Tablets to Enhance Solubility of Atorvastatin using Experimental Design

Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015

Asian Journal of Research in Pharmaceutical Sciences and Biotechnology

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota

Role of PBPK based virtual trials modeling in generic product development and regulation

DRAFT GUIDANCE DOCUMENT ADDENDUM - Quality (Chemistry and Manufacturing) Guidance: Questions and Answers

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space

CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION

The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G

Extractables & Leachables. Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies

Kollidon The Original Setting new standards in stability, purity and patient safety.

Research Article. Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets

Industrial & Sys Eng - INSY

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

Appendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version)

Quality by Design, Revolution or Evolution? Wim Oostra

DRUG SOLUBILITY EXECUTIVE SUMMARY

University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester

PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products

WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability

Answer ALL questions. Use the answer grid provided for ALL of your answers. For each of the following questions there is ONE correct answer only.

Accelerating development of enabled formulations for poorly soluble drugs

GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product

INTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!

PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS

Vol - 4, Issue - 4, Jul-Sept 2013 ISSN: Soni et al PHARMA SCIENCE MONITOR

In vitro in vivo correlations (IVIVC) can be summarized

Typical excipients in a tablet formulation. Glidant SiO 2

Guidelines for Pharmaceutical Equivalence Requirements

COMPRESSIVE STRENGTH MODELING OF SCC USING LINEAR REGRESSION AND ARTIFICIAL NEURAL NETWORK APPROACH

Establishment of Wheat Yield Prediction Model in Dry Farming Area Based on Neural Network

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services

f a c t s T C C T B Tricalcium citrate as excipient for direct compression

Biowaivers: BCS and IVIVC

Day-Ahead Price Forecasting of Electricity Market Using Neural Networks and Wavelet Transform

SUPAC IR/MR Update. Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013

Handbook Controlled Release Of Drugs Polymers And Aggregate Systems

Implementation of QBD for Analytical Methods - Session Introduction -

Regulatory Requirements of Dissolution for Generic Drug Products

Overview of Statistics used in QbD Throughout the Product Lifecycle

How to Identify Critical Quality Attributes and Critical Process Parameters

Process Design Risk Management A Proactive Approach

EVALUATION FOR STABILITY DATA

CHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES

QbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS

Transcription:

Experimental design on product development

Introduction What is the traditional developing method? What is experimental design? What do we need and what kind of possibilities do we have for designing? Why is it useful during product development? Where and how can we use or apply the design results?

Traditional method Developing a hypothesis Conducting an experiment to test the hypothesis Modifying the hypothesis on the basis of the experiment results Conducting an additional experiment based on the modified hypothesis

Drawbacks of the traditional method Limited understanding of variable effect No information about interaction with other components The approach is extremely inefficient Requires too many experiments and too much time Expensive

The developer must work until... a satisfactory result is found all possibilities are exhausted all available time and money are exhausted... Because the... data processing is slow the number of errors is high

What kind of possibilities do we have? Data from previous investigations Experience, knowledge and intuition Computer software neural networks designing models

Biological neuron structure Dendrites Cell body Axon Electrical signal Synapses

Signal transport between neurons Eletrical signal Axon Presynaptic membrane Neurotransmitter material Synaptic gap Postsynaptic membrane Electrical signal

Relationship between biological and artificial neural network system (ANN) Linear Treshold gate Treshold value

What is artificial neural network? A modelling tool that discovers a relationship from a database of examples An automatic mathematical construction method for modelling preparations directly from data A cost-effective possibility for designing a new preparation

What is needed for design? Pre-examination results of the substances to be used Know the final dose or the final pharmaceutical form Determination of preparation parameters Test results of the preparation

Application areas of ANN Pattern recognition Economic and social models Financial sector Marketing modeling Optimization of investments Telecommunication Signal Analysis Data compression Environmental Protection Industry Weather forecast Quality control Biology Manufacturing Planning Fault Diagnosis

General characteristics of ANN 1. It consists of nodes and links between the knots the weighted input of the input signals is calculated the amount is compared with the threshold(s) linear or nonlinear transmission function their "behavior" changes their behavior and the links between the knots 2. It can be divided into three main parts an interconnected network of nodes the node activation rule the learning rule for nodes

Applied ANNs Associating networks Feature extracting networks Nonadaptive networks Back-propagation model

One and more "hidden" layers of neural systems

Bayesian network (Generalized Regression Neural Network) Hidden layer Regression layer Input layer Output layer

Data modeling system Stuttgart Neural Network Simulator

Other applied ANNs Box-Behnken Central composite Algorithm: back-propagation Pseudo-random Resilient Propagation (Rprop) Resilient Propagation with MAximum-Posterior (Rprop-MAP)

Determining the number of hidden neurons M.N. Jadid et al: Eng.Appl.Artif.Intell. 9 (1996) 303-319 J.C. Carpenter et al: AI Expert 10 (1995) 31-33

The optimization of the node number of the "hidden" layer depends on: the number of inbound and outbound neurons the number of data used to teach the "noise level" of the desired value the complexity of the function you want to teach the type of neural network from the activation value of hidden nodes from the teaching algorithm

How does a neural network work? Data collection Determination of variables and parameters Data input into the computer Teaching and checking Application of knowledge

What do we need? Input parameters Output parameters effective materials disintegrants fillers binders glidants lubricants etc. particle size flow properties hardness friability disintegration time dissolution rate etc.

Predicted and experimental dissolution values Y1 Y2 Y3 Y4 P E P E P E P E F1 47,00 47,03 74,66 74,69 92,61 92,62 103,4 103,4 F2 21,38 21,36 47,17 47,16 91,38 91,42 102,3 102,3 F3 13,81 13,81 21,61 21,61 33,95 33,94 47,49 47,48 F4 17,03 17,03 26,23 26,22 47,02 46,99 67,21 67,19 F5 14,06 14,06 21,81 21,81 32,86 32,85 49,55 49,54 F6 23,12 23,12 50,35 50,36 80,40 80,44 99,16 99,19 F7 17,02 16,66 30,08 29,81 49,79 49,87 67,44 68,76 F8 17,02 17,37 30,08 30,35 49,79 49,71 67,44 66,11 F9 14,47 14,46 26,46 26,44 42,44 42,41 62,08 62,06 F10 36,11 36,11 65,80 65,80 77,18 77,17 99,43 99,43

Release profiles of ASA from model formulations

Response surfaces of the influence of the percentage of Eudragit L 100 and tablet hardness on the percentage of ASA released after (A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 8 hours, predicted using the GRNN.

Contour plots of the influence of percentage of Eudragit L 100 and tablet hardness on percentage of ASA released after (A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 8 hours, predicted using the GRNN.

Predicted and experimental observed Aspirin release from optimal formulation.

Crack velocity and film opacity response surfaces

Experimental design

What does experimental design involve? A practice that employs statistical tools and methods in scientific experimenting Variables via which we are attempting to make a correlation or regression with a measurable input and output we are trying to predict

What is necessary for designing Preliminary investigations of the materials The dosage and the dosage form of the final product Determination of the parameters of the preparation process Results of the investigations of the preparations

Preliminary investigations

Designing a pellet

Designing the experiment

Design method selection Central composite Face centered Box-Behnken Simplex Equiradial Random Simplex centroid Simplex Lattice Hybrid

Detailing of the experiments

Parameterizing the ANN

Setting the control parameters

Setting up the parameters

Investigated compositions

Results of investigations 1.

Results of investigations 2.

Finding the best or worst sample

Importance of ingredients

Querying a new sample

Predicting the properties 1.

Predicting the properties 2.

Material and method Granule: API: Filler: Disintegrant: Binder: Dilthiazem HCl (Dilt) Vivapur 101 (V101) Era-Tab (Era-T) Pharmacoat 603 (P603) Desing mode: Preparation: Hybrid design Freund CF-360 granulator

Design the core Dilt Era-T V101 P603 Min. Max. Min. Max. Min. Max. Min. Max. 100 g 500 g 300 g 500 g 100 g 500 g 10 g 40 g

Designed compositions Dilt Era-T V101 P603 (g) (g) (g) (g) MST-1 315 339 346 23 MST-2 144 440 417 36 MST-3 471 413 116 17 MST-4 426 408 166 23 MST-5 374 453 173 19 MST-6 342 378 280 23 MST-7 365 420 215 21

Granule preparation

Preparation conditions Liqu. add. Rotor Temp ml/min rpm C MST-1 10 140 45 MST-2 10 140 45 MST-3 15 160 45 MST-4 15 160 55 MST-5 20 200 55 MST-6 20 200 65 MST-7 20 200 65

Investigated properties MST-1 MST-2 MST-3 MST-4 MST-5 MST-6 MST-7 Density Roundness Hardness Friability (N) (%) 1,649 1,19 0,751 0,15 1,753 1,17 0,747 0,12 1,583 1,29 0,729 0,18 1,651 1,16 0,746 0,23 1,678 1,25 0,757 0,31 1,731 1,22 0,781 0,17 1,939 1,19 0,731 0,19

Shape of granules

Parameterizing the ANN

Editing the training parameters

Structure of ANN

Control parameters

Prediction of density

Prediction of hardness

Prediction of friability

Prediction of roundness

Searching for samples or parameters

Directed search

Areas where it is useful Area Application Applied DoE TYPE Oral drug delivery Tablet formulation development Multivariate design (fractional factorial design in 14 variables, 2 14 9 design, 35 experiments) Multivariate design + simplex optimization by Modde Optimizer Fractional factorial designs (two studies); design space definition using a simplified Bayesian Monte Carlo simulation Oral drug delivery immediate release (IR) Mixture design Dispersible tablets development Several factorial experiments at 2 3 factors, 2 3 levels Immediate release tablet platform Resolution V 2 5 1 fractional factorial design Fast dissolving pellets 2 5 1 fractional factorial design, five factors (four numeric and one categorical), two levels Oral drug delivery modified release (MR) Gastroretentive dosage form 3-level-3-factor, Box Behnken design

Area Application Applied DoE TYPE Inhalation drug delivery Powder for inhalation (formulation and process development) Half-fractional factorial design with five factors at two levels with resolution V Face centered central Composite Design with three factors at three levels Risk assessment by Lean QbD Software Transdermal drug delivery Patch development 2 4 full factorial design Iontophoretic delivery Face-centered central composite design (total number of experimental combinations 2 k +2k + n 0, with k = number of independent variables and n 0 = number of repetitions of the experiments at the center point) Cutaneous drug delivery (Topical) Ocular drug delivery Nanoemulsion for leishmaniasis (formulation development) Microsponge-based gel for surgical wounds (development) PEGylated PLGA nanospheres (optimization and characterization) 2 2 full factorial design 3-factor, 3-level Box Behnken design Central composite factorial design Liquid crystalline nanoparticles (formulation optimization) Fractional factorial design 2 5 1 ; simplex-lattice experimental design

Area Application Applied DoE TYPE Injections Biopharmaceuticals Formulation for parenteral nutrition (development) Toward QbD implementation in the biopharmaceutical industry QbD for biopharmaceuticals QbD for risk assessment and management (Case Study on Monoclonal Antibody) D-optimal experimental design (mixture design) Nanopharmaceutics Antibody Formulation Robustness Protein formulation Development and industrialization of polymeric targeted nanoparticle drug delivery platforms Multivariate study (full factorial) including three factors at two levels Solid Lipid Nanoparticles for Inhalation (process development) Two-level full factorial design (with no center points and three repetitions for each level)

Area Application Applied DoE TYPE Pharmaceutical processes Dry powder inhaler capsule filling D-optimal model with design statistics G- efficiency with three replicates Excipient micronization Freeze-drying of injectables Film-formation by spraying Full factorial (three variables at two levels, eight runs) Design space calculation (according to a cited model) Rechtschaffner Res V two-level fractional design for four variables with center point Nano-precipitation and nanospray-drying Design model based on integrated-variance optimal design for surface response Analytical methods Method (e.g. chromatographic) development Test methods Adhesion test (for patches) Randomized response surface design, five factors, 38 runs In vitro aerosol deposition in human cast (for inhaled products) Half-factorial design Generic drug products Generic product equivalence Fractional factorial design with triplicate center points

Conclusions It is necessary to know the properties of the materials The dosage form and the final dosage of the preparation must be known for the preliminary investigations It is possible to determine the optimal parameters of the preparation process It can generally be used for the development of new products

The benefits of computerized design Short data-processing time Economical design Fewer errors Better preparation More profit